bisphosphonates | Horse Racing Free Tips

California Horse Racing Board Issues Bisphosphonate Complaint Against Jeff Metz

The California Horse Racing Board issued a complaint against trainer Jeff Metz last week over a finding of bisphosphonates in the Sept. 27, 2020 post-race sample of the gelding Camino De Estrella, reports the Daily Racing Form. The drugs are not yet specifically classified in California, so the positive is being adjudicated under the “prohibited substances” rule with a Class 1, Category A penalty.

However, Metz's attorney Darrell Vienna believes the trainer will be exonerated. Popular at the claim box, Camino de Estrella has been in the care of five different trainers since 2019, including Tim Yakteen, Mark Glatt, Steve Knapp, Metz, and most recently Bill Spawr.

“There is a record of a veterinarian administering the drug when he was not in Mr. Metz's care, in 2019,” Vienna told DRF. “I can say with certainty that Jeff never administered bisphosphonates to that horse. We're confident that the truth will come out, because we think the CHRB already knows the truth.”

Bisphosphonates were approved for equine use in the United States approximately six years ago, to treat horses with symptoms of navicular syndrome, a common, nagging foot pain in older horses. Before the drugs were approved for horses in the U.S., they were used in Europe and veterinarians could legally import them to treat American horses. Having them available to American practitioners who perhaps couldn't previously afford the import process has made a world of difference to mature horses dealing with navicular syndrome – and there are a lot of them. Roughly a third of chronic front leg lamenesses are believed to be related to navicular pain. Generally, bisphosphonates have been safe and effective in the population they're intended for.

Bisphosphonates (sold commercially as Osphos and Tildren) are FDA-approved in horses four years old and up, and are not approved for use in mares who are pregnant or lactating. The reason for those restrictions is unanswered questions about potential side effects. Bisphosphonates do their work by reducing the action of cells called osteoclasts, which clear away damaged bone and make way for osteoblasts to lay down new bone. In a young equine skeleton, this could disrupt the growth cycle.

The CHRB did prohibit the administration of bisphosphonates beginning July 1, 2020, via rule 1867.1, which also prohibits any horse from entering CHRB grounds that has been administered the drug within six months.

Since Camino de Estrella would have been five years old in 2019, administration of a bisphosphonate was legal at that time only if the gelding had a diagnosis of navicular disease.

Vienna argued that “the available science on bisphosphonates clearly demonstrates that the drug can be found more than 2 1/2 years after the drugs have been administered, due to their unique ability to lie dormant in bone but become 'active' in the horse's circulatory system when bone is in need of repair.”

Bisphosphonate Complaint Issued Against Metz By CHRB

A complaint involving a banned bisphosphonate has been lodged by the California Horse Racing Board (CHRB) against trainer Jeffrey Metz, summoning him to a stewards' hearing.

According to a CHRB complaint dated Apr. 29, a positive for tiludronic acid was confirmed via split-sample testing from Camino de Estrella (Mineshaft), who finished sixth in the third race Sept. 27, 2020, at Santa Anita.

The now-7-year-old gelding was claimed that day for $20,000, and has finished no better than sixth in four subsequent starts for a four-way partnership that includes trainer Bill Spawr.

The complaint states that, “Tiludronic Acid is considered a prohibited drug substance Class 1 Penalty Category A,” which is the most severe classification.

However, tiludronic acid is not specifically listed as an individual substance on the CHRB's “Classification of Foreign Substances” list, which is modeled after the Uniform Classification Guidelines for Foreign Substances list published by the Association of Racing Commissioners International (ARCI).

But a separate CHRB rule states that, “Any drug or its metabolite or analogue thereof found to be present in an official test sample that is not classified in Rule 1843.2 of this division shall be classified as a Class 1 substance and a Category 'A' penalty until classified by the Board.”

On July 1, 2020, the CHRB enacted Rule 1867.1, which broadly prohibits the administration of bisphosphonates to any horse within a facility regulated by the CHRB and also prohibits any horse from entering the grounds if it has been administered a bisphosphonate within the prior six months (effectively making the rule retroactive to Jan. 1, 2020).

According to the ARCI's ruling database, Metz has two medication violations within the past five years, one each for Class 3 (xylazine in 2018, fined $250) and Class 4 (triamcinolone acetonide in 2016, fined $300). Both occurred at Emerald Downs, where he has won four training titles, and on both occasions the stewards there cited Metz's lack of a history of medication violations in issuing penalties for those two offenses.

In California, the recommended penalties for first-time Class 1 violations by a trainer call for a minimum one-year suspension and a minimum fine of $10,000, although mitigating circumstances can be taken into consideration.

The complaint states that “the horse shall be disqualified and any purse money forfeited.” The complaint lists the owners of Camino de Estrella at the time of the positive test as Jeffrey West (Saratoga West), Scott Gruender (Horseplayers Racing Club) and Jeremy Hodges.

No date for a stewards' hearing was listed on the complaint.

The post Bisphosphonate Complaint Issued Against Metz By CHRB appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

TERF Awards $20k to the University Of Pennsylvania School Of Veterinary Medicine

The Thoroughbred Education and Research Foundation (TERF) has awarded $20,000 to the University Of Pennsylvania School Of Veterinary Medicine to be used for equine research.

In alignment with their mission to support and promote equine research, TERF annually provides grant funding to organizations that are engaged in the research of issues which impact equine health.

Funding will be used to support research by Mary Robinson, VMD, PhD in a study of the use of bisphosphonates to medically treat equines. Bisphosphonates inhibit bone breakdown and are useful for treating bone disorders in horses.

The study will provide evidence for a better understanding of the impact of the use of bisphosphonates in the treatment of Thoroughbreds for these issues which can significantly impact an equine’s quality of life.

The post TERF Awards $20k to the University Of Pennsylvania School Of Veterinary Medicine appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Annual UK Equine Research Showcase To Take Place Virtually

University of Kentucky Ag Equine Programs will host its 10th annual UK Equine Showcase virtually through four sessions over four dates in January and February 2021.The event will continue the “life journey” theme initiated last year and will emphasize weanling to yearling horses, presenting both completed and work-in-progress projects relevant to this age group.

“We are excited to once again put together an excellent set of lectures and continuing education featuring many of our colleagues,” said Emma Adam, assistant professor and research and industry liaison at the Gluck Equine Research Center. ““The way our industry is helped through the resources we have at the University of Kentucky is unparalleled.”

Due to the current pandemic, the event has moved to a virtual format. Organizers wanted to continue to provide information and continuing education opportunities in 2021 rather than postpone for a year. Recognizing that staying engaged for long periods of time via a virtual format is challenging, organizers chose to break up the annual event into several shorter sessions over the course of a few weeks.

Jan. 5, 6-7:30 p.m. EST, will focus on musculoskeletal issues and include the following topics and speakers:

Bisphosphonates, NSAIDs and other medicines in the juvenile horse with Scott Stanley, professor of analytical chemistry at the Gluck Equine Research Center.
Sesamoid bone maturation by the laboratory of James MacLeod, director of UK Ag Equine Programs and John S. and Elizabeth A. Knight chair and professor of veterinary science at the Gluck Center.
Bone pathology in Wobbler's Syndrome with Jennifer Janes, assistant professor of anatomic pathology at UK's Veterinary Diagnostic Laboratory.

Jan. 19, 6-7:30 p.m. EST, will focus on nutrition and pasture topics and include the following information and speakers:

Mineral requirements for a growing horse with Mieke Brummer-Holder, assistant professor in the Department of Animal and Food Sciences.
Amino acids and protein synthesis in the growing horse with Kristine Urschel, associate professor in the Department of Animal and Food Sciences.
UK Horse Pasture Evaluation Program information with Krista Lea, program coordinator, and Ray Smith, professor and extension forage specialist, both from the Department of Plant and Soil Sciences.

Feb. 2, 6-7:30 p.m. EST, will focus on parasitology, vaccination immunology and causes of mortality and include the following information and speakers:

Vaccination, immunity and immune response in weanlings with David Horohov, chair of the Department of Veterinary Science, director of and Jes E. and Clementine M. Schlaikjer Endowed Chair at the Gluck Center.
Parasitology as it pertains to weanlings and yearlings with Martin Nielsen, Schlaikjer professor of Equine Infectious Disease at the Gluck Center.
Common(est) causes of mortality in this age group with Laura Kennedy, assistant professor and veterinary pathologist at the UK VDL.

Feb. 9, 6-7:30 p.m. EST will cover hot topics in a mini session format of 10 minutes each, with updates about equine research literature resources at UK, nocardioform placentitis summary from 2020, COVID-19 economic impact and the next equine survey, lab updates, Equine Biological Passport update, genetic diversity project, updates on equine surface research, important parasitology updates and more.

“This is a unique and special outreach event. The purpose is to showcase some of what is happening at the University of Kentucky in terms of scientific discovery and service efforts relevant to the young horse,” MacLeod said. “Participants will hopefully gain new information they can apply to their programs, but importantly also a greater appreciation for some of the critical questions being addressed at UK, why these issues are important and where the cutting edge of research is on a number of very interesting topics. This annual program, now reaching 10 years, highlights our commitment to advance research, service and teaching for the benefit of horses and the equine community.”

The UK Equine Showcase is open to veterinarians, owners and managers of all horse breeds or anyone with an interest in learning more about foals and horse management. Its virtual format means that this opportunity is open to attendees from across the U.S. and even world.

The cost to attend all sessions is $25 until the early-bird registration deadline of Jan. 5. This package will include a PDF of the presentations and access to a recording of the sessions after the event has concluded. Attendees can also opt to attend only one or two of the sessions they are interested in. Individual event registration will also be available for $10 each. There are special rates for farms interested in having multiple employees attend. Students from any university can participate for free. Please contact equine@uky.edu for help in registering for those discounted or free sessions. Continuing education credit for veterinarians and veterinary technicians is pending approval by the Kentucky Board of Veterinary Examiners. Register here. Contact equine@uky.edu with questions about the event or with help registering.

UK is also accepting sponsor participation for the showcase. Presenting opportunities are available to participating organizations on a first-come, first-served basis. Email equine@uky.edu for details.